Update shared on 22 Nov 2025
Fair value Increased 3.64%The analyst price target for Medpace Holdings has increased from $519 to $538. Analysts cite improving Biotech market confidence and stronger forward earnings projections as factors supporting this upward revision.
Analyst Commentary
Recent street research on Medpace Holdings reflects a range of perspectives regarding the company’s valuation, execution, and growth outlook. Multiple analysts have updated their price targets following discussions with management and assessments of recent market trends.
Bullish Takeaways- Bullish analysts have lifted their price targets, with some assuming higher forward earnings multiples in light of the improving Biotech market and confidence in ongoing sector recovery.
- Improved book-to-bill ratios and increased pipeline values, with one firm highlighting 30% year-over-year pre-backlog pipeline growth, point to strengthening demand fundamentals.
- Stabilizing healthcare utilization and cost trends are viewed as positive indicators for ongoing managed care operations and Medpace’s future performance.
- Recent quarters showed stronger Biotech funding and improved industry bookings. This signals momentum across the contract research organization landscape and supports expectations for solid results.
- Some bearish analysts continue to maintain cautious ratings, citing concerns that consensus estimates may not adequately reflect persistent lower-than-normal book-to-bill numbers in the first half of 2025. This could weigh on 2026 revenue and adjusted EBITDA growth.
- While funding and demand have improved, there are indications that overall industry demand signals remain mixed. This has prompted continued caution regarding the near-term outlook.
- Certain outlooks have been tempered by the possibility that recent improvements may be more moderate than previously forecasted. This keeps some analysts skeptical about rapid acceleration in sector growth.
What's in the News
- Medpace Holdings repurchased 14,649 shares, representing 0.05 percent, for $4.53 million between July 1, 2025 and September 30, 2025. To date, the company has completed the repurchase of 4,498,399 shares, representing 14.81 percent, for $1,278.29 million since the buyback program announcement in October 2022 (Key Developments).
- The company issued new earnings guidance for full year 2025, projecting revenue between $2.480 billion and $2.530 billion. This represents an increase of 17.6 percent to 20.0 percent over 2024 revenue. Forecasted GAAP net income is between $431.0 million and $439.0 million, with diluted earnings per share in the range of $14.60 to $14.86 (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has risen from $519.36 to $538.25. This reflects increased optimism about Medpace Holdings' future valuation.
- Discount Rate has edged slightly lower, moving from 7.73 percent to 7.73 percent. This indicates marginally reduced risk or cost of capital assumptions.
- Revenue Growth projections have increased from 12.19 percent to 12.55 percent, suggesting expectations for improved top-line expansion.
- Net Profit Margin estimates have risen modestly, up from 17.32 percent to 17.42 percent. This indicates anticipated improvements in operational efficiency or profitability.
- Future P/E Ratio has increased from 24.77x to 25.28x. This reflects higher anticipated earnings multiples assigned by the market.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.